Administration and Regulation of Activities associated with The Vanderbilt Urologic Infection Repository, a Resource for Personalized Clinical Discovery

范德比尔特泌尿感染信息库(个性化临床发现资源)相关活动的管理和监管

基本信息

项目摘要

SUMMARY - ADMINISTRATIVE CORE We propose the Vanderbilt Urologic Infection Repository (VUIR) as a first-in-kind resource for host-pathogen discovery, one that systematically connects [1] medical data from a vast number of patients who suffer from urinary tract infections (UTIs) to [2] a biobank of the actual causative organisms. As an informatic and biologic network, the VUIR will facilitate novel diagnostic and therapeutic strategies to combat UTIs, while providing a tool to elucidate their underlying pathogenesis. At the same time—given the extensive scope of the VUIR and its potential for multidisciplinary innovation—the need arises for a strong administrative foundation to coordinate the program's daily activities and bring to fruition its scientific vision. To these ends, a critical strength of the VUIR will be its associated Administrative Core (AdCore), a defined personnel structure for organizational success. The faculty leadership team of the AdCore holds broad expertise in clinical urology (Dr. Douglass Clayton), microbial pathogenesis (Dr. Maria Hadjifrangiskou), and clinical pathology/laboratory medicine (Dr. Jonathan Schmitz), further supported by both a Local Executive Committee and External Advisory Committee. These groups will likewise include strategic representation from informaticians, infectious disease specialists, hospital epidemiologists, and microbiome experts, providing ongoing thematic direction to the VUIR from the diverse fields to which the program will contribute. The AdCore will also incorporate dedicated logistical support from professionals with extensive background in academic and financial administration, as well as web-site design and event management. In total, this group will ensure that our logistical operations are both proactive and responsive, coordinating interactions and disseminating specimens/data within and beyond Vanderbilt. The AdCore will create synergy between the VUIR and complementary institutional structures for precision medicine and translational discovery, as well as champion pilot projects that build upon VUIR resources. Our ultimate goal, however, is to create a network of affiliated collaborators across the United States, clinicians and investigators who could both benefit from and contribute to the combined wealth of data and specimens. Finally, in addition to supporting scientific innovations, the AdCore will ensure we develop a concomitant footprint in education and service. Through a combination of workshops, seminars, and immersive experiences, we will connect nationwide experts in urogenital infection-biology to diverse trainees, from undergraduate students to postdoctoral/clinical fellows. In addition to content-area education, these interactions will foster networking and career-development experiences, including opportunities for individuals from underrepresented groups. And reaching beyond academia, the AdCore will promote outreach to the larger community, building on existing Vanderbilt programs to educate the public on our scientific mission. In this way, this administrative foundation of the VUIR will maximize the program's ability to generate discoveries, while disseminating information to broad and varied audiences.
摘要 - 行政核心 我们提出了范德比尔特泌尿科感染库(VUIR)作为宿主病原体的第一款资源 发现,系统地将[1]的医疗数据连接起来。 尿路感染(UTI)对[2]实际因果生物的生物库。作为一个信息和生物学 网络,Vuir将促进新颖的诊断和治疗策略来对抗UTI,同时提供 阐明其潜在发病机理的工具。同时 - 构成了Vuir的广泛范围 它进行多学科创新的潜力 - 有强大的行政基础需要协调 该计划的日常活动并带来科学愿景。到这些目的, Vuir将是其关联的行政核心(Adcore),这是组织的定义人员结构 成功。 Adcore的教师领导团队拥有临床泌尿外科的广泛专业知识(Douglass博士) Clayton),微生物发病机理(Maria Hadjifrangiskou博士)和临床病理学/实验室医学(博士 乔纳森·施密茨(Jonathan Schmitz),由地方执行委员会和外部咨询委员会进一步支持。 这些群体同样将包括来自Informativeans,感染疾病专家的战略代表, 医院流行病学家和微生物组专家,为Vuir提供了持续的主题指导 该计划将贡献的各个领域。该广告还将包含专用的后勤支持 来自具有学术和金融管理方面广泛背景的专业人员以及网站 设计和活动管理。总体而言,该小组将确保我们的后勤操作都是主动的 以及响应迅速的协调相互作用,并在范德比尔特(Vanderbilt)内外传播标本/数据。这 Adcore将在Vuir和完整的精确医学机构结构之间产生协同作用 并翻译了基于Vuir Resources的冠军飞行员项目。我们的最终目标 但是,是在美国,临床医生和调查人员之间建立一个会员合作者网络 谁可以从数据和标本的综合财富中受益并贡献。最后,除了 支持科学创新,广告将确保我们在教育和 服务。通过研讨会,半手和沉浸式体验的结合,我们将在全国范围内建立联系 从本科生到博士后/临床,泌尿生殖感染生物学专家 研究员。除了内容区域教育外,这些互动还将促进网络和职业发展 经验,包括来自代表性不足群体的个人的机会。并到达 Acadeia,Adcore将在现有的Vanderbilt计划的基础上促进向大型社区的宣传 向公众教育我们的科学任务。这样,Vuir的行政基础将 最大化该计划的生成发现的能力,同时将信息传播到广泛而多样 受众。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Maria Hadjifrangiskou其他文献

Maria Hadjifrangiskou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Maria Hadjifrangiskou', 18)}}的其他基金

Targeting cytochrome bd as an anti-biofilm strategy
靶向细胞色素 bd 作为抗生物膜策略
  • 批准号:
    10642243
  • 财政年份:
    2023
  • 资助金额:
    $ 10.02万
  • 项目类别:
How E. coli Acid Response Mechanisms Breach Colonization Resistance in the Vagina
大肠杆菌酸反应机制如何突破阴道定植抗性
  • 批准号:
    10657442
  • 财政年份:
    2022
  • 资助金额:
    $ 10.02万
  • 项目类别:
Two-component system interactions as uropathogenic Escherichia coli drug targets
作为尿路致病性大肠杆菌药物靶标的两组分系统相互作用
  • 批准号:
    8816807
  • 财政年份:
    2014
  • 资助金额:
    $ 10.02万
  • 项目类别:
Two-component system interactions as uropathogenic Escherichia coli drug targets
作为尿路致病性大肠杆菌药物靶标的两组分系统相互作用
  • 批准号:
    9252820
  • 财政年份:
    2014
  • 资助金额:
    $ 10.02万
  • 项目类别:
Two-component system interactions as uropathogenic Escherichia coli drug targets
作为尿路致病性大肠杆菌药物靶标的两组分系统相互作用
  • 批准号:
    9172228
  • 财政年份:
    2014
  • 资助金额:
    $ 10.02万
  • 项目类别:
Administration and Regulation of Activities associated with The Vanderbilt Urologic Infection Repository, a Resource for Personalized Clinical Discovery
与范德比尔特泌尿感染存储库(个性化临床发现资源)相关的活动的管理和监管
  • 批准号:
    10022301
  • 财政年份:
  • 资助金额:
    $ 10.02万
  • 项目类别:
The Vanderbilt Urologic Infection Repository, a Resource for Personalized Clinical Discovery
范德比尔特泌尿感染存储库,个性化临床发现的资源
  • 批准号:
    9913352
  • 财政年份:
  • 资助金额:
    $ 10.02万
  • 项目类别:
The Vanderbilt Urologic Infection Repository, a Resource for Personalized Clinical Discovery
范德比尔特泌尿感染存储库,个性化临床发现的资源
  • 批准号:
    10022306
  • 财政年份:
  • 资助金额:
    $ 10.02万
  • 项目类别:

相似海外基金

The Utah Regional Network for Excellence in Neuroscience Clinical Trials
犹他州神经科学临床试验卓越区域网络
  • 批准号:
    8529637
  • 财政年份:
    2011
  • 资助金额:
    $ 10.02万
  • 项目类别:
The Utah Regional Network for Excellence in Neuroscience Clinical Trials
犹他州神经科学临床试验卓越区域网络
  • 批准号:
    8709000
  • 财政年份:
    2011
  • 资助金额:
    $ 10.02万
  • 项目类别:
The Utah Regional Network for Excellence in Neuroscience Clinical Trials
犹他州神经科学临床试验卓越区域网络
  • 批准号:
    8337836
  • 财政年份:
    2011
  • 资助金额:
    $ 10.02万
  • 项目类别:
The Utah Regional Network for Excellence in Neuroscience Clinical Trials
犹他州神经科学临床试验卓越区域网络
  • 批准号:
    8241308
  • 财政年份:
    2011
  • 资助金额:
    $ 10.02万
  • 项目类别:
Short Course: Integrative and Organ Systems Pharmacology
短期课程:综合和器官系统药理学
  • 批准号:
    7232109
  • 财政年份:
    2005
  • 资助金额:
    $ 10.02万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了